The adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
SP Industries Announces Brian Larkin as President and CEO
AppointmentsSP Industries Inc. has announced the appointment of Brian Larkin as its President and Chief Executive Officer effective February 19th, replacing William (Bill) Downs who recently retired.
Sanofi’s alirocumab improves cardiovascular event rate over statins
Latest NewsAlirocumab, Sanofi’ s/Regeneron’s PCSK9 inhibitor, in combination with statins has met the endpoint of reducing the number of major adverse cardiovascular events (MACE) over statin monotherapy in 18,924 high-risk patients.
Medimmune finds target against systemic sclerosis
Latest NewsResearchers at Medimmune, AstraZeneca’s biologics arm, have identified a mechanism that drives the autoimmune disease systemic sclerosis.
Bioprocessing challenges in the focus
Latest NewsLearning to listen to your gut
BackgroundThe adage you are what you eat’ is more than folk wisdom. Evidence that the food you ingest has a major impact on your health grows by the day. It’s now clear the bacteria that colonise the skin and gut from birth on are key sensors for environmental triggers in chronic diseases of civilisation. Ever since research showed that restoring microbiome balance cures 90% of all Clostridium difficile infections, food manufacturers, pharma companies and independent teams have been tracking it in other indications – including multiple sclerosis.
Sanofi to outsource antiinfectives R&D to Evotec
Latest NewsEvotec and Sanofi want to create an Evotec-led infectious disease open innovation R&D platform at Sanofi’s antiinfectives hub in Lyon. Talks are expected to close in H1/2018 with an option agreement.
David Colpman joins Forendo Pharma’s Board of Directors
AppointmentsForendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
Parexel Appoints Jamie Macdonald as CEO
AppointmentsCompany Co-founder Josef von Rickenbach to retire after 35 years of leadership; serve as Chairman of the Board.
Experts forecast the industry’s biggest developments at Pharmapack Europe
BackgroundPersonalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.
Heidelberg Pharma inks US$334m R&D contract with Magenta Therapeutics
Latest NewsUnder an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.